Markets:

Overview

News

Currencies

International

Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

29.67 +0.89 (+3.09%)

Streaming Delayed Price Updated: 10:31 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge ↗

November 19, 2025

Via Stocktwits

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal ↗

November 14, 2025

Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior.

Via Benzinga

Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid ↗

November 14, 2025

A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center.

Via Investor's Business Daily

Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes ↗

November 14, 2025

Avadel’s board of directors is of the opinion that the fresh proposal would reasonably be expected to be considered superior to the company’s existing agreement with Alkermes.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Preview: Alkermes's Earnings ↗

October 27, 2025

Via Benzinga

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study ↗

November 12, 2025

Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulness and sleepiness scores.

Via Benzinga

This Alkermes Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗

November 11, 2025

Via Benzinga

ALKERMES PLC (NASDAQ:ALKS) Q3 2025 Earnings Beat Estimates and Drive Stock Surge ↗

October 28, 2025

Alkermes (ALKS) Q3 2025 earnings crush estimates with a 58% EPS beat and $394.2M revenue. The company raises its full-year 2025 financial guidance.

Via Chartmill

Topics Earnings

Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups ↗

October 24, 2025

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors.

Via Benzinga

Topics Government

Breaking Down Alkermes: 8 Analysts Share Their Views ↗

October 23, 2025

Via Benzinga

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz ↗

October 22, 2025

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.

Via Benzinga

Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition

October 22, 2025

DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for...

Via MarketMinute

Topics Intellectual Property

Avadel Jumps On $2.1 Billion Takeover Deal. But Buyer, Alkermes, Dives. ↗

October 22, 2025

The companies are both working in the sleep space, focusing on excessive daytime sleepiness.

Via Investor's Business Daily

Avadel Stock Rises After Acquisition Offer By Alkermes ↗

October 22, 2025

Alkermes will buy Avadel for up to $20 per share.

Via Stocktwits

9 Analysts Assess Alkermes: What You Need To Know ↗

September 26, 2025

Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts. The following table encapsulates their recent ratings, offering a glimpse...

Via Benzinga

This Ciena Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

September 26, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

Deep Dive Into Alkermes Stock: Analyst Perspectives (7 Ratings) ↗

September 03, 2025

Via Benzinga

Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗

September 03, 2025

Via Benzinga

This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 03, 2025

Via Benzinga

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 03, 2025

Via Benzinga

ALKERMES PLC (NASDAQ:ALKS) Emerges as a Top Value Pick with Strong Fundamentals and Undervalued Metrics ↗

August 05, 2025

ALKERMES PLC (ALKS) is a strong value stock with low P/E ratios, high profitability, and a debt-free balance sheet, making it an attractive pick for long-term investors.

Via Chartmill

Alkermes PLC (NASDAQ:ALKS) Surges 7.8% Pre-Market After Q2 2025 Earnings Beat Revenue and EPS Estimates ↗

July 29, 2025

Alkermes PLC (ALKS) reported strong Q2 2025 results, beating revenue and EPS estimates, driving a 7.8% pre-market rally. The company reaffirmed full-year guidance, signaling confidence in growth.

Via Chartmill

Topics Earnings

Alkermes Q2 Sales Up 14 Percent ↗

July 29, 2025

Via The Motley Fool

Topics Intellectual Property

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. ↗

July 21, 2025

All four companies are testing out orexin agonists to improve the symptoms of narcolpesy.

Via Investor's Business Daily

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study ↗

July 21, 2025

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability across all doses.

Via Benzinga

Expert Outlook: Alkermes Through The Eyes Of 6 Analysts ↗

July 15, 2025

Via Benzinga

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗

July 07, 2025

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.